Clinical Trial Update: Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating an immunomodulatory therapy for high-risk solitary bone plasmacytoma is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmacytoma

Snippet

Sponsor: University College, London | Conditions: Plasmacytoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING